Role of antiischemic agents in the management of non-ST elevation acute coronary syndrome (NSTE-ACS)

Cardiovascular Therapeutics

Volumn 30, Issue 1, 2012, Pages

  El Kadri, Moutaz ^a   Sharaf Dabbagh, Hala ^a   Ramsdale, David ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

Antianginal; Antiischemic; Beta blockers; Calcium channel blockers; Nitrates; Non ST elevation acute coronary syndrome (NSTE ACS)

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIISCHEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; DILTIAZEM; FASUDIL; FELODIPINE; IVABRADINE; METOPROLOL; NEBIVOLOL; NICORANDIL; NIFEDIPINE; NITRATE; PERHEXILINE; PINDOLOL; PROPRANOLOL; RANOLAZINE; SILDENAFIL; TRIMETAZIDINE; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL ISCHEMIA; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84856265110     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00225.x     Document Type: Review

References (100)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics-2010 Update. A Report From the American Heart Association. Circulation 2009;121:e1-e170.
2. Task FM, Bassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007;28:1598-1660.
3. Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156:1026-1034.
4. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358-363.
5. Goodman SG, Huang W, Yan AT, et al. The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J 2009;158:193-201.
6. Furman MI, Dauerman HL, Goldberg RJ, Yarzbeski J, Lessard D, Gore JM. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: A multi-hospital, community-wide perspective. J Am Coll Cardiol 2001;37:1571-1580.
7. White HD. Evolution of the definition of myocardial infarction: What are the implications of a new universal definition? Heart 2008;94:679-684.
8. Fox KAA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-1900.
9. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: Observations from an unselected cohort. Eur Heart J 2005;26:18-26.
10. Gregor RD, Bata IR, Brownell B, Wolf HK. Trends in the in-hospital treatment of acute myocardial infarction between 1984 and 1. Can J Cardiol 2000;16:596-603.
11. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001;103:3062-3068.
12. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516.
13. Zipes D, Libby P, Bonow R, et al. Braunwald's heart disease: A textbook of cardiovascular medicine, 8th ed., Philadelphia: Saunders, 2008.
14. Yamagishi M, Terashima M, Awano K, et al. Morphology of vulnerable coronary plaque: Insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000;35:106-111.
15. Clarke MCH, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006;12:1075-1080.
16. Geng YJ, Libby P. Progression of atheroma: A struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002;22:1370-1380.
17. Van Der Wal AC, Becker AE, Van Der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
18. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
19. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
20. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
21. Ardissino D, Merlini PA, Ariδns R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. J Lancet 1997;349:769-771.
22. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: Further evidence for the existence of the "vulnerable" patient. Circulation 2004;110:1926-1932.
23. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
24. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
25. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without st-segment elevation in various risk groups. Circulation 2002;106:1622-1626.
26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
27. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. J Lancet 2010;375:283-293.
28. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. J Lancet 2002;359:189-198.
29. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815.
30. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
31. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J 2007;28:2077-2086.
32. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-2216.
33. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of Fondaparinux and Enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
34. Brodde OE, Michel MC. Adrenergic and Muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-690.
35. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 2000;87:1095-1102.
36. Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 2006;98:1115-1119.
37. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: Focus on nebivolol. J Cardiovasc Pharmacol 2009;54:123-128.
38. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341-1362.
39. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C.
40. Ryden L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983;308:614-618.
41. Doo YC, Kim DM, Oh DJ, Ryu KH, Rhim CY, Lee Y. Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris. Am J Cardiol 2001;88:422-424.
42. Sipahi I, Tuzcu EM, Wolski KE, et al. +|-Blockers and progression of coronary atherosclerosis: Pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 2007;147:10-18.
43. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318:1730-1737.
44. Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group. Am J Cardiol 1985;56:39G-46G.
45. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: Findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987;60:18A-25A.
46. Muller JE, Turi ZG, Pearle DL, et al. Nifedipine and conventional therapy for unstable angina pectoris: A randomized, double-blind comparison. Circulation 1984;69:728-739.
47. Hohnloser SH, Meinertz T, Klingenheben T, Sydow B, Just H. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group. Am J Cardiol 1991;67:1319-1323.
48. Brunner M, Faber TS, Greve B, et al. Usefulness of Carvedilol in unstable angina pectoris. Am J Cardiol 2000;85:1173-1178.
49. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: A randomized, double-blind, placebo- controlled trial. Circulation 1986;73:331-337.
50. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263.
51. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
52. Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007;120:685-692.
53. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: Pooled results from the Epic, Epilog, Epistent, Capture and Rapport Trials. J Interv Cardiol 2003;16:299-305.
54. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol 2008;52:2046-2099.
55. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: A meta-analysis. Respir Med 2003;97:1094-1101.
56. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009;103:295-300.
57. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
58. Wier WG, Egan TM, Lopez-Lopez JR, Balke CW. Local control of excitation-contraction coupling in rat heart cells. J Physiol 1994;474:463-471.
59. Bers DM. Excitation-contraction coupling and cardiac contractile force. Dordrecht: Kluwer Academic Publishers, 2003.
60. Opie L, Gersh B. Drugs for the heart. Philadelphia: Saunders (W.B.) Co Ltd., 2001.
61. Bers DM, Perez-Reyes E. Ca channels in cardiac myocytes: Structure and function in Ca influx and intracellular Ca release. Cardiovasc. Res. 1999;42:339-360.
62. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: The Trent study. Br Med J (Clin Res Ed) 1986;293:1204-1208.
63. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). Eur Heart J 1988;9:354-364.
64. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-747.
65. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-353.
66. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
67. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985;5:717-722.
68. Parodi O, Simonetti I, L'Abbate A, Maseri A. Verapamil versus propranolol for angina at rest. Am J Cardiol 1982;50:923-928.
69. Andre-Fouet X, Usdin JP, Gayet C, et al. Comparison of short-term efficacy of diltiazem and propranolol in unstable angina at rest: A randomized trial in 70 patients. Eur Heart J 1983;4:691-698.
70. Boden WE, Krone RJ, Kleiger RE, et al. Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. The Multicenter Diltiazem Post-Infarction Trial Research Group. Am J Cardiol 1991;67:335-342.
71. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-429.
72. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-528.
73. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-785.
74. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. BMJ 1989;299:1187-1192.
75. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clin Cardiol 1998;21:633-641.
76. Surks HK. cGMP-dependent protein kinase I and smooth muscle relaxation: A tale of two isoforms. Circ Res 2007;101:1078-1080.
77. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
78. DePace NL, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med 1982;142:1806-1809.
79. Roubin GS, Harris PJ, Eckhardt I, Hensley W, Kelly DT. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust N Z J Med 1982;12:598-602.
80. Karlberg KE, Saldeen T, Wallin R, Henriksson P, Nyquist O, Sylven C. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: A double-blind placebo-controlled study. J Intern Med 1998;243:25-31.
81. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials. Lancet 1988;1:1088-1092.
82. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-1122.
83. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58, 050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685.
84. Jahangir A, Terzic A. KATP channel therapeutics at the bedside. J Mol Cell Cardiol 2005;39:99-112.
85. Kukovetz WR, Holzmann S, Poch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol 1992;20(Suppl 3):S1-S7.
86. Yellon DM, Baxter GF, Marber MS. Angina reassessed: Pain or protector?. Lancet 1996;347:1159-1162.
87. Effect of nicorandil on coronary events in patients with stable angina: The impact of nicorandil in angina (IONA) randomised trial. J Lancet 2002;359:1269-1275.
88. Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: A meta-analysis. Circ J 2009;73:925-931.
89. Nishimura M, Tokoro T, Nishida M, et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: A randomized trial. Am J Kidney Dis 2009;54:307-317.
90. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the KATPchannel in unstable angina: Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. Eur Heart J 1999;20:51-57.
91. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006;92:iv6-iv14.
92. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-1783.
93. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina: Observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (metabolic efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-1516.
94. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-1652.
95. Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current. J Mol Cell Cardiol 2010;48:55-64.
96. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
97. Koster R, Kaehler J, Meinertz T. Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION study. Am Heart J 2009;158:e51-e57.
98. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005;CD003614, doi:.
99. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-1811.
100. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev 2007;25:76-97.